What is Rubius Therapeutics, Inc.'s current stock price?

Rubius Therapeutics, Inc. (RUBY) currently trades at USD 0.0570. Track real-time price changes and historical performance on AllInvestView.

What sector is Rubius Therapeutics, Inc. in?

Rubius Therapeutics, Inc. operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

Rubius Therapeutics, Inc. RUBY · Stock Open Rubius Therapeutics, Inc. in new tab

0.0570 USD

Add to portfolio

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Rubius Therapeutics, Inc. (RUBY)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Rubius Therapeutics, Inc. Analysis (RUBY)

United States Health Care Official Website Stock

Is Rubius Therapeutics, Inc. a good investment? Rubius Therapeutics, Inc. (RUBY) is currently trading at 0.0570 USD.

Investor FAQ

Does Rubius Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Rubius Therapeutics, Inc.?

Rubius Therapeutics, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

Company Profile

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Exchange Ticker

FRA (Germany) 5RT.F

MUN (Germany) 5RT.MU

NMS (United States) RUBY

Trades

No dividend information available for this instrument.

Rubius Therapeutics, Inc. RUBY · Stock Open Rubius Therapeutics, Inc. in new tab

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Rubius Therapeutics, Inc. Analysis (RUBY)

Investor FAQ

Company Profile

Fundamentals

Under Construction

Rubius Therapeutics, Inc. RUBY · Stock Open Rubius Therapeutics, Inc. in new tab

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Rubius Therapeutics, Inc. Analysis (RUBY)

Investor FAQ

Company Profile

Explore Premium Features

Fundamentals

Under Construction

Community Discussion

Notifications